<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments on: From Vytorin To Whytorin? The Enhance Saga</title>
	<atom:link href="http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/feed" rel="self" type="application/rss+xml" />
	<link>http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/</link>
	<description>News, Comment and Conversation</description>
	<pubDate>Fri, 10 Feb 2012 20:07:02 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.6.2</generator>
		<item>
		<title>By: CarolM</title>
		<link>http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/#comment-238967</link>
		<dc:creator>CarolM</dc:creator>
		<pubDate>Tue, 01 Apr 2008 04:07:15 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/#comment-238967</guid>
		<description>Waiting for an answer to John's question.  I am also on Vytorin but thinking of calling my physician to request a change. It is so upsetting  and the more articles I read on the net just confuse me more.</description>
		<content:encoded><![CDATA[<p>Waiting for an answer to John&#8217;s question.  I am also on Vytorin but thinking of calling my physician to request a change. It is so upsetting  and the more articles I read on the net just confuse me more.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: John Bonner</title>
		<link>http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/#comment-225317</link>
		<dc:creator>John Bonner</dc:creator>
		<pubDate>Tue, 25 Mar 2008 05:35:00 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/#comment-225317</guid>
		<description>Will someone please give me a straight answer?

I have been taking Vytorin for a year. I am extremely pleased with the numbers for my LDL (lower) and it seems to have improved my HDL (higher). However, I read in the Harvard Health Letter (HHL April 2008, p.1), to which I subscribe, the following:”There’s been bad news about … and most recently, the cholesterol-lowering combination of ezetimibe and simvastatin (Vytorin).” Another issue of the HHL implied that one might be worse off taking Vytorin than a straight statin, such as simvastatin (Zocor), which I used to take. 

I’m truly nonplussed. What should I do? I’m inclined to stay with Vytorin, but I’d sure like someone to address this issue more carefully.</description>
		<content:encoded><![CDATA[<p>Will someone please give me a straight answer?</p>
<p>I have been taking Vytorin for a year. I am extremely pleased with the numbers for my LDL (lower) and it seems to have improved my HDL (higher). However, I read in the Harvard Health Letter (HHL April 2008, p.1), to which I subscribe, the following:”There’s been bad news about … and most recently, the cholesterol-lowering combination of ezetimibe and simvastatin (Vytorin).” Another issue of the HHL implied that one might be worse off taking Vytorin than a straight statin, such as simvastatin (Zocor), which I used to take. </p>
<p>I’m truly nonplussed. What should I do? I’m inclined to stay with Vytorin, but I’d sure like someone to address this issue more carefully.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: www.worldpharmanews.net</title>
		<link>http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/#comment-224421</link>
		<dc:creator>www.worldpharmanews.net</dc:creator>
		<pubDate>Mon, 24 Mar 2008 12:20:37 +0000</pubDate>
		<guid isPermaLink="false">http://www.pharmalot.com/2008/03/from-vytorin-to-whytorin-the-enhance-saga/#comment-224421</guid>
		<description>&lt;strong&gt;Pharmalot » From Vytorin To Whytorin? The Enhance Saga...&lt;/strong&gt;

As the American College of Cardiology meeting nears this coming weekend in Chicago, the curtain raisers have begun to appear. Last week, Forbes set the stage by discussing why the full study results, which will be presented for the first time, are impo...</description>
		<content:encoded><![CDATA[<p><strong>Pharmalot » From Vytorin To Whytorin? The Enhance Saga&#8230;</strong></p>
<p>As the American College of Cardiology meeting nears this coming weekend in Chicago, the curtain raisers have begun to appear. Last week, Forbes set the stage by discussing why the full study results, which will be presented for the first time, are impo&#8230;</p>
]]></content:encoded>
	</item>
</channel>
</rss>

<!-- Dynamic Page Served (once) in 0.150 seconds -->

